Disc Medicine (NASDAQ: IRON) stock rose 38.86% on Oct. 19, 2026, to $78.93, a 39.33% gain from the Oct. 15 close over two sessions. Benzinga, GuruFocus and a Seeking Alpha call transcript reported that the company's pivotal APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), a rare light-sensitivity disease, was positive. After the market closed on Oct. 19, the company announced a proposed stock offering, which matters because it can add shares and dilute existing owners.
Key facts
- Oct. 19, 2026: IRON closed at a latest-quote price of $78.93, up 38.86% on the day. Its 52-week range is $40 to $99.50.
- Oct. 15 to Oct. 19, 2026: The two-session change was 39.33%. Market value is about $3.03B.
- Oct. 19, 2026 (4:01 p.m. ET): According to its GlobeNewswire release, Disc announced an underwritten public offering of common stock and pre-funded warrants (warrants to buy shares at a nominal remaining cost). It is subject to market conditions and may change in size or not complete.
- Quarter ended June 30, 2026: Revenue was $0.00. Net loss was $59.5M, or $1.54 per share, versus a $55.2M loss, or $1.58 per share, in the quarter ended June 30, 2025.
- As of June 30, 2026: Cash and short-term investments were $717.7M against total debt of $60.9M.
- Next earnings date: Nov. 5, 2026.
What happened
The cause, as reported: on Oct. 19, 2026, several outlets covered topline results from APOLLO, the pivotal late-stage trial of bitopertin in EPP. Benzinga described a successful study, and GuruFocus described positive results. Seeking Alpha posted a transcript of the company's call on the data. Those reports are the only explanation for the move that the available news supports. We are not reporting trial figures here because they are not in our verified data set. Readers should check the company's release for the specifics.
The company describes itself as a clinical-stage biopharmaceutical firm focused on serious blood diseases. Its release says bitopertin is aimed at EPP and X-linked protoporphyria (XLP). In a clinical-stage company, one trial readout can change how the market values the whole business, because there are no sales yet to anchor the price.
After the close, Disc announced the proposed offering. According to its release, it plans to use the proceeds, together with existing cash, for research and development, to support the potential commercialization of bitopertin in EPP and XLP, for pre-commercialization work on other candidates, and for general corporate purposes. Jefferies, Leerink Partners, Morgan Stanley and Cantor are the joint book-running managers. The release also says underwriters would get an option to buy additional shares. The sale uses a shelf registration the company filed with the SEC in 2024. We do not have data on how the stock traded after hours or on the final price and size.
Why it matters for investors
The business today. Disc has no revenue. Its net loss over the last five quarters has stayed within a fairly narrow band: -$55.2M (quarter ended June 30, 2025), -$62.3M (Sept. 30, 2025), -$60.5M (Dec. 31, 2025), -$63.5M (March 31, 2026) and -$59.5M (June 30, 2026). Margins cannot be calculated without sales. Cash burn is the better gauge. Free cash flow, meaning cash from operations minus capital spending, was -$44.2M in the June 2026 quarter, after -$62.2M in the March quarter and -$43.3M in the December 2025 quarter. What changed is that the March quarter was the heaviest burn of the five, and the June quarter returned close to the year-ago level of -$48.0M. The company said nothing in the materials we have that explains the swing, so we do not speculate on why.
Cash cushion. At $717.7M, cash was large relative to the quarterly burn, and debt-to-equity was 0.09. The Altman Z-score, a bankruptcy-risk gauge, was 18.85, which is a strong reading. The Piotroski score, a nine-point scale of financial health that rewards profitability, was 1. That low reading is normal for a company with no profits, and it is a weak spot. The proposed offering would add cash, but it would also raise the share count.
Valuation versus peers. IRON's trailing price-to-earnings ratio was -11.96. The negative sign only means losses. Among peers in our comparison set, Geron (GERN, market cap $771.0M) was at -12.04 with a net margin of -34.2%. Agios (AGIO, $2.08B) was at -4.98 with a net margin of -418.2%. Hemab Therapeutics (COAG, $1.50B) was at -24.50, and Damora Therapeutics (DMRA, $1.19B) was at -0.15. At $3.03B, Disc is the largest of this group. Comparing loss-making biotechs on earnings multiples says little, so size and pipeline stage matter more.
Analysts. FMP data shows 11 ratings: 1 strong buy and 10 buy, with no holds or sells, for a consensus of Buy. Analyst price targets average $109.83 with a median of $117.50, a high of $128 and a low of $86. The $78.93 price sits below even the lowest target. Cantor Fitzgerald maintained its Overweight rating on Oct. 19. These are analysts' views, not ours. Targets can move quickly after trial data and a financing.
Stock Expert AI's MoonshotScore. A MoonshotScore for IRON was not included in the data used for this article, so we are not quoting one or describing its pillars.
What could go wrong.
- The offering is proposed, not final. Its size, price and timing are uncertain, and the company itself says it may not be completed. New shares can reduce each existing share's slice of the company.
- Insider activity leans toward selling. Among the most recent filings, there were 0 open-market purchases and 18 sales in the last 90 days, though older filings in that window may be missing. Insider sales are often routine, but they are a data point.
- FMP's discounted cash flow model puts fair value at $2.31 per share. We treat that as a limit of the model, which struggles with companies that have no sales yet, rather than a verdict. It does show that the price rests on expectations for bitopertin rather than current results.
- The release lists the usual risks: stock price swings, market conditions and the pending offering.
What to watch next
- The pricing of the offering: the final size, price and any warrant terms, expected in the company's SEC filings and a follow-up release.
- The Nov. 5, 2026 earnings report: analysts expect a loss of $1.63 per share and revenue of $1.9M.
- Regulatory steps for bitopertin: the release refers to potential commercialization, but we have no confirmed filing or approval dates, so watch for company updates.
- Longer-range estimates: the two analysts covering the quarter ending March 30, 2027 expect a loss of $1.81 per share and no revenue. For the quarter ending June 30, 2027, they expect a $1.88 loss and revenue of $580,000.
Frequently asked questions
Q: Why did Disc Medicine stock go up on Oct. 19, 2026?
According to Benzinga, GuruFocus and a Seeking Alpha call transcript, the company reported positive results from its pivotal APOLLO trial of bitopertin in EPP. The stock rose 38.86% that day to $78.93.Q: Is Disc Medicine selling more shares?
According to its Oct. 19, 2026 release, the company announced a proposed underwritten public offering of common stock and pre-funded warrants after the market closed. It is subject to market conditions and may not be completed as described. Selling shares can dilute existing holders.Q: Is Disc Medicine profitable?
No. In the quarter ended June 30, 2026, the company had no revenue and a net loss of $59.5M, or $1.54 per share. It held $717.7M in cash and short-term investments as of June 30, 2026. Its next earnings report is due Nov. 5, 2026.This is educational content, not investment advice. Past performance does not guarantee future results.